Biotechnology company developing transformative therapies for genetic diseases.
PepGen Inc., headquartered in Cambridge, Massachusetts, is an innovative clinical-stage biotechnology company dedicated to advancing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases. Established in 2018, PepGen focuses on pioneering treatments that address critical unmet medical needs in these challenging conditions.
Central to PepGen's pipeline is its lead product candidate, PGN-EDO51, an EDO peptide currently undergoing Phase I clinical trials for Duchenne muscular dystrophy (DMD). This therapy aims to provide novel therapeutic options for individuals affected by this debilitating genetic disorder.
In addition to PGN-EDO51, PepGen is actively developing PGN-EDODM1, a peptide-conjugated PMO designed for the treatment of myotonic dystrophy type 1, another severe neuromuscular condition. The company's innovative approach extends to other EDO therapeutic candidates, including PGN-EDO53, PGN-EDO45, and PGN-EDO44, all aimed at addressing different aspects of DMD and potentially offering new avenues for disease management.
Through strategic partnerships and collaborations with leading research institutions, PepGen accelerates the development of its therapeutic pipeline. By harnessing cutting-edge technologies and scientific expertise, PepGen remains committed to advancing transformative treatments that improve the lives of patients suffering from severe neuromuscular and neurologic diseases worldwide.